Editorial disclosure: This article is original educational commentary based on the cited literature. It summarizes and interprets published evidence rather than reproducing source text. Clinical decisions should be based on the full original publications, current guidelines, regulatory status, and individual patient factors.
The two-number model is expanding
Chronic kidney disease is often reduced to eGFR and urine albumin-to-creatinine ratio. These measures remain indispensable, but the diagnostic landscape is changing toward improved filtration markers, albuminuria, biopsy, multi-omics, advanced imaging, artificial intelligence and risk prediction.
Cystatin C and albuminuria
Cystatin C provides an alternative filtration marker that is less dependent on creatinine generation. Combined creatinine–cystatin C equations can improve confidence when creatinine is potentially misleading. Albuminuria is both a marker of kidney damage and a powerful predictor of cardiovascular and kidney outcomes; eGFR and albuminuria together identify markedly different risk states.
Biopsy, imaging and AI
Kidney biopsy remains essential when histologic diagnosis will alter management. Molecular profiling may reveal disease mechanisms not obvious from conventional microscopy. Advanced imaging and computational analysis may eventually characterize fibrosis, perfusion and tissue architecture non-invasively, while AI is being investigated for case detection, image interpretation and individualized risk prediction.
A biomarker is clinically useful only if it is standardized, accessible, validated in diverse populations and linked to a decision that improves outcomes. The future is therefore likely to be a layered diagnostic model rather than one replacement test.
Key clinical takeaways
- eGFR and albuminuria remain foundational.
- Cystatin C, biopsy, imaging, multi-omics and AI may expand precision.
- Implementation, validation and equity remain major barriers.
References
- Lees JS, et al. Advances in the diagnosis and detection of chronic kidney disease. Lancet. 2026;407(10546):2414–2428. DOI.